The advent of biologics has transformed the therapeutic landscape of moderate-to-severe psoriasis, particularly agents targeting interleukin-17 (IL-17) and interleukin-23 (IL-23), which have demonstrated rapid onset of action, long-term efficacy, and high rates of skin clearance [7,8]. The gene discussed is IL17A; the disease is psoriasis.